| Filed On | Filing |
|---|---|
| 16 Nov 2026 | NT 10-Q |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Fifth Side Letter — Closing under Series B Preferred Purchase Agreement |
| 05 Nov 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Certain personal information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***]” |
| 29 Oct 2026 |
8-K: Other Events
Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way for Therapeutic Efficacy Evaluation |
| 27 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Re: Fourth Side Letter — Closing under Series B Preferred Purchase Agreement |
| 26 Oct 2026 |
8-K: Other Events
Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod |
| 22 Oct 2026 |
8-K: Other Events
Interim CEO Dean Zikria’s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company’s integrated capabilities |
| 20 Oct 2026 | EFFECT |
| 20 Oct 2026 | EFFECT |
| 21 Oct 2026 | 424B3 |
| 16 Oct 2026 | REGISTRATION STATEMENT |
| 16 Oct 2026 | DEFINITIVE PROXY STATEMENT |
| 15 Oct 2026 |
8-K: Other Events
Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, vi... |
| 14 Oct 2026 |
8-K: Other Events
With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge |
| 08 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Third Side Letter — Closing under Series B Preferred Purchase Agreement |
| 08 Oct 2026 | REGISTRATION STATEMENT |
| 06 Oct 2026 |
8-K: Other Events
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing |
| 05 Oct 2026 | DRS |
Loading...